Vical plummets on placebo promise in herpes study
This article was originally published in Scrip
San Diego-based Vical's stock was cut almost in half on 23 June after the company reported that the placebo in a Phase I/II clinical trial outperformed both the monovalent and bivalent forms of its therapeutic genital herpes vaccine by a wide margin. In terms of the trial's primary endpoint, viral shedding decreased 12% for patients treated with the monovalent vaccine, 19% in the study's bivalent arm and 45% in the placebo group.
You may also be interested in...
Company will focus on getting oral anti-fungal candidate VL-2397 over the finish line, after another pipeline blow-up.
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.